This analysis looks at J.B. Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) across the metrics that matter most to fundamental investors: revenue trajectory, profitability, valuation, and ownership trends.
JB Chemicals Revenue Trend
J.B. Chemicals & Pharmaceuticals Ltd. grew revenue 7.4% to ₹4,208 Cr in FY2026, up from ₹3,918 Cr in the prior year.
Over a 10-year span, revenue at J.B. Chemicals & Pharmaceuticals Ltd. has compounded at 13.1% annually, a rate that comfortably outpaces inflation.
At ₹4,208 Cr in annual revenue, J.B. Chemicals & Pharmaceuticals Ltd. sits squarely in mid-sized territory within the pharmaceuticals sector.
J.B. Chemicals & Pharmaceuticals Ltd. has now delivered 10 consecutive years of revenue growth, a consistency that few mid-cap peers manage to sustain.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹4,208 Cr | +7.4% |
| FY2025 | ₹3,918 Cr | +11.3% |
| FY2024 | ₹3,521 Cr | +11.5% |
| FY2023 | ₹3,159 Cr | +28.2% |
| FY2022 | ₹2,463 Cr | — |
View J.B. Chemicals & Pharmaceuticals Ltd.'s full 10-year revenue trend with CAGR analysis →
JB Chemicals Profitability
Net profit at J.B. Chemicals & Pharmaceuticals Ltd. reached ₹709 Cr in FY2026, a 7.6% improvement over the prior year.
A net margin of 16.9% in FY2026 reflects stable profitability, holding roughly level with the previous year.
Diluted EPS grew from ₹41.56 in FY2025 to ₹44.45 in FY2026, tracking the underlying earnings improvement.
Is JB Chemicals Undervalued
Using the P/E Ratio model, J.B. Chemicals & Pharmaceuticals Ltd.'s fair value works out to ₹1,890, which is 23.2% downside from the current trading price.
Shares of J.B. Chemicals & Pharmaceuticals Ltd. are currently priced at ₹2,460.00.
Beyond the P/E model, Craytheon calculates intrinsic value using both the EPS Growth and DCF approaches. Assumptions and the full breakdown are available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹1,890 | 23.2% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for J.B. Chemicals & Pharmaceuticals Ltd. with detailed assumptions →
JB Chemicals Shareholding Pattern
Promoters have been adding to their position, with the stake climbing from 47.7% to 48.8% over 4 quarters.
Foreign institutional investors have trimmed their exposure, with FII ownership at 16.3% versus 17.8% a year ago.
Domestic institutional investors have been building their position, with the holding rising to 21.4% as of March 2026 from 19.6% a year earlier.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 48.8% | 16.3% | 21.4% | 13.5% |
| Dec 2025 | 47.5% | 14.9% | 23.4% | 14.2% |
| Sep 2025 | 47.6% | 15.3% | 22.8% | 14.3% |
| Jun 2025 | 47.7% | 17.8% | 19.6% | 14.9% |
Track quarterly shareholding changes for J.B. Chemicals & Pharmaceuticals Ltd. →
JB Chemicals Balance Sheet
Proportional view as of 13 Jul 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2026, the total asset base came in at ₹49.69B, up 16.3% YoY from ₹42.74B.
Intangibles & Goodwill accounts for 25.6% of the total, ahead of Cash & ST Investments (17.1%) and Receivables (15.7%).
Capital structure: 83.7% equity, 0.1% debt, 16.2% operating liabilities. Over the year, debt is down 87.1% and equity is up 21.1%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 8.49B |
| Receivables | 7.81B |
| Inventories | 6.83B |
| Property, Plant & Equipment | 6.54B |
| Investments | 260.30M |
| Intangibles & Goodwill | 12.74B |
| Other Assets | 7.01B |
| Category | Value |
|---|---|
| Equity | 41.59B |
| Short-term Debt | 24.65M |
| Long-term Debt | 11.25M |
| Trade Payables | 3.91B |
| Other Liabilities | 4.15B |
What Stands Out About JB Chemicals
Taken together, here is how J.B. Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) stacks up for fundamental analysts.
FY2026 revenue of ₹4,208 Cr, up 7.4% from the prior year.
Long-term revenue growth runs at 13.1% compounded annually over 10 years.
The company is profitable, with a net margin of 16.9% and net income of ₹709 Cr.
The P/E Ratio model implies 23.2% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for J.B. Chemicals & Pharmaceuticals Ltd. includes three valuation models, decade-long financials, and insider activity.